A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. METHODS: We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. RESULTS: ). Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides PNPLA3 p.I148M and TM6SF2 p.E167K, additional variants, including common risk variants in MBOAT7 , GCKR , GPAM , protective variants in HSD17B13 , APOE and MTARC1, and rare variants ( e.g. in APOB , MTTP, CIDEB and ATG7 ), have been robustly associated with the risk of progressive MASLD. 199 -205”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the periportal hepatocyte-enriched genes HSD17B13152 and PNPLA3153 are associated with NASH”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“To demonstrate this, we examined the trans associations with a splice variant in HSD17B13 (rs72613567), known to protect against chronic liver disease42.”
From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [42]
In the citing paper
“These findings inform the prioritization of therapeutic targets, providing clues to potential on-target side effects and opportunities for drug repurposing87–89.”
From A brief history of human disease genetics (2020) · cites this paper as [88]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Cited by
Items 201–300 of 830
The role of IFN in the development of NAFLD and NASH
Møhlenberg, M., Terczynska-Dyla, E., Thomsen, K. L., George, J., Eslam, M., Grønbæk, H., & Hartmann, R. (2019) · Cytokine · doi:10.1016/j.cyto.2018.08.013 · Cited by 50
Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets
Bianco, C., Casirati, E., Malvestiti, F., & Valenti, L. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100284 · Cited by 50
The influence of host genetics on liver microbiome composition in patients with NAFLD
Pirola, C. J., Salatino, A., Quintanilla, M. F., Castaño, G. O., Garaycoechea, M. E., & Sookoian, S. C. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103858 · Cited by 50
Update on genetics and epigenetics in metabolic associated fatty liver disease
Zhu, X., Xia, M., & Gao, X. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221132138 · Cited by 54
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
MASLD in children: integrating epidemiological trends with mechanistic and translational advances
Schwimmer, J. B., Biddinger, S. B., & Ibrahim, S. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186422 · Cited by 57
“The HSD17B13 rs72613567:TA variant, the first known protective polymorphism in MASLD, reduces the risk of progression from steatosis to steatohepatitis in both adults (63) and children (64).”
HSD17B13 and Chronic Liver Disease in Blacks and Hispanics
Kozlitina, J., Stender, S., Hobbs, H. H., & Cohen, J. C. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1804027 · Cited by 48
Self-citationGenetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA
Campani, C., Zucman‐Rossi, J., & Nault, J. (2023) · Cancers · doi:10.3390/cancers15030817 · Cited by 54
Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502978122 · Cited by 46
“The hydroxysteroid 17 - beta dehydrogenase 13 (HSD17B13) splice site variant (rs72613567) decreases the risk of MASH (29).”
Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications
Martin, K., Hatab, A., Athwal, V. S., Jokl, E. J., & Hanley, K. P. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01377-5 · Cited by 48
Gentilucci, U. V., Gallo, P., Dell’Unto, C., Volpentesta, M., Incalzi, R. A., & Picardi, A. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i43.4835 · Cited by 48
Lipid Droplet Formation and Lipophagy in Fatty Liver Disease
Schulze, R. J., & McNiven, M. A. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1685524 · Cited by 55
Non-alcoholic fatty liver disease: a narrative review of genetics
Christopher, J., Zemin, Y., & Z., G. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.32.20180045 · Cited by 45
“Most recently, exome-wide sequencing has identified the rs72613567:TA variant within hydroxysteroid 17beta dehydrogenase 13 (HSD17B13), which was associated with a decreased risk of alcoholic liver disease, NASH, alcoholic cirrhosis, and NASH cirrhosis([53]).”
BackgroundInfluentialPal, P., Palui, R., & Ray, S. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1584 · Cited by 55
Contribution of a genetic risk score to ethnic differences in fatty liver disease
Kubiliun, M. J., Cohen, J. C., Hobbs, H. H., & Kozlitina, J. (2022) · Liver International · doi:10.1111/liv.15322 · Cited by 45
Self-citationChen, V. L., Kuppa, A., Oliveri, A., Chen, Y., Ponnandy, P., Patel, P. B., Palmer, N. D., & Speliotes, E. K. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186424 · Cited by 60
“Several studies (5, 15, 18, 24–42) (summarized in Table 2) with genome-wide coverage, e.g., array or sequencing, have assessed genetic associations with hepatic steatosis using imaging and/or histology as a discovery and/or validation phenotype. but consistent with the other study, decreased…”
InfluentialKoo, B. K., Joo, S. K., Kim, D., Lee, S., Bae, J. M., Park, J. H., Kim, J. H., Chang, M. S., & Kim, W. K. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.02.011 · Cited by 49
Ting, Y., Kong, A. S.-Y., Zain, S. M., Chan, W., Tan, H., Mohamed, Z., Pung, Y. F., & Mohamed, R. B. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0162 · Cited by 47
Pais, R., & Maurel, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061161 · Cited by 52
“, presence and clustering of the metabolic traits) [71], biological (transaminases levels) [92] and genetic (PNPLA3, TM6SF2, HSD17B13) [93,94] factors allow for a “general” estimation of the HCC risk, these approaches are not accurate enough to justify the implementation of the screening strategies in the absence of c…”
BackgroundPSD3 downregulation confers protection against fatty liver disease
Mancina, R. M., Sasidharan, K., Lindblom, A., Wei, Y., Ciociola, E., Jamialahmadi, O., Pingitore, P., Andréasson, A., Pellegrini, G., Baselli, G., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-021-00518-0 · Cited by 47
“20 Ballooning 106 (32) 72 (25) 18 (29) 0.”
Fred, R. G., Steen Pedersen, J., Thompson, J. J., Lee, J., Timshel, P. N., Stender, S., Opseth Rygg, M., Gluud, L. L., Bjerregaard Kristiansen, V., Bendtsen, F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16754-7 · Cited by 44
Self-citationNonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers
Basu, R., Noureddin, M., & Clark, J. M. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.04.005 · Cited by 50
“1702 progression from steatosis to steatohepatitis.(29,30)”
Liu, W., Iwamoto, N., Marappan, S., Luu, K., Tripathi, S., Purcell-Estabrook, E., Shelke, J. D., Shah, H., Lamattina, A., Pan, Q., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad268 · Cited by 44
“The enhanced potency and durability observed with stereopure GalNAc-siRNAs designed to silence HSD17B13 RNA expression that contain PN chemistry was particularly promising, with a single 1.5 mg/kg subcutaneous dose leading to ∼75% silencing for at least 3 months in mice.”
MethodInfluentialFouad, Y. M., Lazarus, J. V., Negro, F., Peck‐Radosavljevic, M., Sarin, S. K., Ferenci, P., Esmat, G., Ghazinian, H., Nakajima, A., Silva, M., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16346 · Cited by 47
Schneider, C. V., Schneider, K. M., Conlon, D. M., Park, J., Vujkovic, M., Zandvakili, I., Ko, Y.-A., Trautwein, C., Carr, R. M., Strnad, P., et al. (2021) · Med · doi:10.1016/j.medj.2021.04.011 · Cited by 44
Self-citationThe role of microbiota in nonalcoholic fatty liver disease
Ciaula, A. D., Bonfrate, L., & Portincasa, P. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13768 · Cited by 45
Wang, M., Li, J., Li, H., Dong, B., Jiang, J., Liu, N., Tan, J., Wang, X., Lei, L., Li, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.2139/ssrn.4065600 · Cited by 63
Glucokinase regulatory protein: a balancing act between glucose and lipid metabolism in NAFLD
Zhang, Z., Ji, G., & Li, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1247611 · Cited by 56
The contribution of genetics and epigenetics to MAFLD susceptibility
Moretti, V., Romeo, S., & Valenti, L. V. C. (2024) · Hepatology International · doi:10.1007/s12072-024-10667-5 · Cited by 53
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review
Sergi, C. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158462 · Cited by 55
“According to Abul-Husn et al. [89], the mutation rs72613567:TA of HSD17B13 is also linked to a decreased likelihood of developing chronic liver disease and progressing from steatosis to steatohepatitis.”
BackgroundRuissen, M. M., Mak, A. L., Beuers, U., Tushuizen, M. E., & Holleboom, A. G. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0065 · Cited by 43
17B-hydroxysteroid dehydrogenases as acyl thioester metabolizing enzymes
Hiltunen, J. K., Kastaniotis, A. J., Autio, K. J., Jiang, G., Chen, Z., & Glumoff, T. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.11.012 · Cited by 43
The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients
Luukkonen, P. K., Qadri, S. U., Lehtimäki, T. E., Juuti, A., Sammalkorpi, H. E., Penttilä, A. K., Hakkarainen, A., Orho‐Melander, M., Arola, J. T., & Yki‐Järvinen, H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa729 · Cited by 43
Hepatocyte nuclear factor 4α in the pathogenesis of non-alcoholic fatty liver disease
Pan, X., & Zhang, Y. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002092 · Cited by 43
“[57] Inhibition of apoptosis by the pan-caspase inhibitors VX166orEmricasan reduces inflammationor thedevelopment of fibrosis in mouse models with NASH.”
BackgroundInfluentialGolabi, P., Owrangi, S., & Younossi, Z. M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17833 · Cited by 63
“50”
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 57
Paternostro, R., Staufer, K., Traussnigg, S., Stättermayer, A. F., Halilbasic, E., Keritam, O., Meyer, E. L., Stift, J., Wrba, F., Sipos, B., et al. (2021) · Hepatology International · doi:10.1007/s12072-021-10200-y · Cited by 44
Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
Pei, Y., & Goh, G. B. (2025) · Gut and Liver · doi:10.5009/gnl240407 · Cited by 52
Epigenetics of alcohol-related liver diseases
Habash, N. W., Sehrawat, T. S., Shah, V. H., & Cao, S. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100466 · Cited by 41
A spotlight on pathogenesis, interactions and novel therapeutic options in NAFLD
Younes, R., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0094-6 · Cited by 42
Chen, Y., Li, R., Hu, N., Yu, C., Song, H., Li, Y., Dai, Y., Guo, Z. Z., Li, M., Zheng, Y., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113227 · Cited by 42
Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases
Hernández-Ceballos, W., Córdova‐Gallardo, J., & Méndez‐Sánchez, N. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00131 · Cited by 45
Emdin, C. A., Haas, M., Khera, A. V., Aragam, K., Chaffin, M., Jiang, L., Wei, W.-Q., Feng, Q., Karjalainen, J., Havulinna, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/594523 · Cited by 40
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments
Prince, D. S., Nash, E., & Liu, K. (2023) · Drugs · doi:10.1007/s40265-023-01939-9 · Cited by 46
“…7 ( MBOAT7 ), and transmembrane 6 superfamily member 2 ( TM6SF2 ), are reproducibly associated with development of cirrhosis with odds ratios (ORs) in the range of 1.5–2.2, while others such as hydroxysteroid 17-beta dehydrogenase 13 ( HSD17B13 ) are protective against disease progression [51–54].”
BackgroundInfluentialNovel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease
Taliento, A. E., Dallio, M., Federico, A., Prati, D., & Valenti, L. V. C. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152755 · Cited by 47
“causes a reduction in the HSD17B13 enzymatic activity [37].”
BackgroundSynergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis
Ciaula, A. D., Bonfrate, L., Krawczyk, M. J., Frühbeck, G., & Portincasa, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052636 · Cited by 41
Omega-3 intake is associated with liver disease protection
Vell, M. S., Creasy, K. T., Scorletti, E., Seeling, K. S., Hehl, L., Rendel, M. D., Schneider, K. M., & Schneider, C. V. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1192099 · Cited by 42
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
Li, W., Alazawi, W., & Loomba, R. S. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00260-2 · Cited by 57
Insights into genetic variants associated with NASH-fibrosis from metabolite profiling
Mann, J. P., Pietzner, M., Wittemans, L. B., Rolfe, E. D. L., Kerrison, N. D., Imamura, F., Forouhi, N. G., Fauman, E., Allison, M. E., Griffin, J. L., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa162 · Cited by 38
“The TA-duplication allele of rs72613567 in HSD17B13 reduces the risk of NAFLD-cirrhosis and mitigates the risk conferred by carriage of the G-allele in PNPLA3 (44).”
BackgroundEssential Biology of Lipid Droplets
Farese, R. V., & Walther, T. C. (2025) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-091724-013733 · Cited by 45
Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
Khneizer, G. W., Rizvi, S., & Gawrieh, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_532 · Cited by 44
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome
Michelotti, A., de Scordilli, M., Palmero, L., Guardascione, M., Masala, M., Roncato, R., Foltran, L., Ongaro, E., & Puglisi, F. (2021) · Cells · doi:10.3390/cells10082034 · Cited by 48
“This loss-offunction variant reduces the risk of developing NAFLD, non-alcoholic cirrhosis [57] and also HCC, even with an alcoholic etiology [58].”
BackgroundThe role of SAMM50 in non‐alcoholic fatty liver disease: from genetics to mechanisms
Li, Z., Shen, W., Wu, G., Qin, C., Zhang, Y., Wang, Y., Song, G., Xiao, C. W., Zhang, X., Deng, G., et al. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13146 · Cited by 36
Advances in the genetics of nonalcoholic fatty liver disease
Ajmera, V. H., & Loomba, R. S. (2023) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000927 · Cited by 41
Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis
Lindén, D., Tesz, G. J., & Loomba, R. S. (2024) · Liver International · doi:10.1111/liv.16186 · Cited by 41
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 48
“This loss-of-function splice variant is particularly beneficial for carriers of the PNPLA3 risk allele, mitigating liver damage [58].”
Subcellular localization and membrane topology of 17β-hydroxysteroid dehydrogenases
Tsachaki, M., & Odermatt, A. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.07.003 · Cited by 36
Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety
Vasandani, C., Li, X., Sekizkardes, H., ADAMS-HUET, B. A., Brown, R. J., & Garg, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa137 · Cited by 36
New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease
Lin, Y., Wu, C.-C., & Ni, Y. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.603654 · Cited by 43
Duwaerts, C. C., Guillou, D. L., Her, C. L., Phillips, N., Willenbring, H., Mattis, A. N., & Maher, J. J. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.050 · Cited by 34
Armandi, A., & Bugianesi, E. (2021) · Liver International · doi:10.1111/liv.14910 · Cited by 38
Gómez, E. V., Pirola, C. J., Sookoian, S. C., Wilson, L., Liang, T., & Chalasani, N. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000400 · Cited by 38
“(3) reported that a loss-offunction splice variant (rs72613567) of the HSD17B13 gene was significantly associated with a lower risk of NAFLD progression and chronic liver disease.”
BackgroundMethodResultInfluentialHuman genetics uncovers MAP3K15 as an obesity-independent therapeutic target for diabetes
Nag, A., Dhindsa, R. S., Mitchell, J., Vasavda, C., Harper, A. R., Vitsios, D., Ahnmark, A., Bilican, B., Madeyski-Bengtson, K., Zarrouki, B., et al. (2022) · Science Advances · doi:10.1126/sciadv.add5430 · Cited by 36
“Of particular interest are loss-of-function alleles that protect against disease since inhibiting their gene products has clear, human-validated precedence for therapeutic intervention (7–9).”
Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2022) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 35
Hudert, C. A., Adams, L. A., Alisi, A., Anstee, Q. M., Crudele, A., Draijer, L. G., EU‐PNAFLD investigators, Furse, S., Hengstler, J. G., Jenkins, B., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1955 · Cited by 45
Kabbani, M., Michailidis, E., Steensels, S., Fulmer, C. G., Luna, J. M., Pen, J. L., Tardelli, M., Razooky, B. S., Ricardo-Lax, I., Zou, C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111321 · Cited by 38
Exome Sequencing in Clinical Hepatology
Vilarinho, S., & Mistry, P. K. (2019) · Hepatology · doi:10.1002/hep.30826 · Cited by 37
“44) Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease.”
BackgroundBaratta, F., D’Erasmo, L., Bini, S., Pastori, D., Angelico, F., Ben, M. D., Arca, M., & Costanzo, A. D. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.011 · Cited by 36
Seko, Y., Yamaguchi, K., Tochiki, N., Yano, K., Takahashi, A., Okishio, S., Kataoka, S., Okuda, K., Umemura, A., Moriguchi, M., et al. (2020) · Liver International · doi:10.1111/liv.14495 · Cited by 34
“AST, IU/L 45 (12-208) 43 (12-142) 51 (15-208) .”
MASLD-Related HCC—Update on Pathogenesis and Current Treatment Options
Leyh, C., Coombes, J. D., Schmidt, H., Canbay, A. E., Manka, P. P., & Best, J. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040370 · Cited by 43
MetALD : New Perspectives on an Old Overlooked Disease
Ayares, G., Díaz, L. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Bataller, R. A., Loomba, R. S., Arab, J. P., & Arrese, M. A. (2025) · Liver International · doi:10.1111/liv.70017 · Cited by 40
Genetic Risk Factors and Disease Modifiers of Nonalcoholic Steatohepatitis
Kozlitina, J. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.09.001 · Cited by 33
Self-citationMarchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 38
Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma
Rajesh, Y., & Sarkar, D. (2020) · Cancers · doi:10.3390/cancers12051290 · Cited by 34
Gut microbiota in MAFLD: therapeutic and diagnostic implications
Alghamdi, W., Mosli, M. H., & Alqahtani, S. A. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241242937 · Cited by 34
Sanyal, A. J., Täubel, J., Badri, P. S., Newton, S. E. B., Makarova, N., Zhao, W., Duggal, S., Kajbaf, F., Olenchock, B. A., & Gansner, J. M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.05.031 · Cited by 32
Dallio, M., Romeo, M., Gravina, A. G., Masarone, M., Larussa, T., Abenavoli, L., Persico, M., Loguercio, C., & Federico, A. (2021) · Nutrients · doi:10.3390/nu13051679 · Cited by 33
Technological readiness and implementation of genomic‐driven precision medicine for complex diseases
Franks, P. W., Melén, E., Friedman, M., Sundström, J., Kockum, I. S., Klareskog, L., Almqvist, C., Bergen, S. E., Czene, K., Hägg, S., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13330 · Cited by 53
Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
Huang, G., Wallace, D. F., Powell, E. E., Rahman, T. M., Clark, P. J., & Subramaniam, V. N. (2023) · Biomedicines · doi:10.3390/biomedicines11102809 · Cited by 33
“Similar to TM6SF2, not much is known about the exact function of the HSD17B13 gene [85].”
BackgroundOligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 35
“350,351 Furthermore, AdV-mediated overexpression of human HSD17B13 led to a fatty liver phenotype in mice, 348 highlighting its role inpromotingNAFLD/NASHpathogenesis.”
BackgroundBourganou, M. V., Chondrogianni, M. E., Kyrou, I., Flessa, C., Chatzigeorgiou, A., Oikonomou, E. K., Lambadiari, V., Randeva, H. S., & Kassi, E. N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041589 · Cited by 38
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Lee, D. H. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.243 · Cited by 35
UDP-glucuronate metabolism controls RIPK1-driven liver damage in nonalcoholic steatohepatitis
Zhang, T., Zhang, N., Xing, J., Zhang, S., Chen, Y., Xu, D., & Gu, J. (2023) · Nature Communications · doi:10.1038/s41467-023-38371-2 · Cited by 33
Distinct hepatocyte identities in liver homeostasis and regeneration
Chen, F., Schönberger, K., & Tchorz, J. S. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100779 · Cited by 30
A decade of liver organoids: Advances in disease modeling
Liu, Y., Sheng, J.-Y., Yang, C.-F., Ding, J., & Chan, Y.-S. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0428 · Cited by 30
Self-citationThe Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum
Vidal‐Cevallos, P., Sorroza-Martínez, A. P., Chávez-Tapia, N. C., Uribe, M., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084397 · Cited by 37
Differences between hepatocellular carcinoma caused by alcohol and other aetiologies
Ganne‐Carrié, N., & Nahon, P. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.030 · Cited by 38
Hong, S. E., Mun, S. J., Lee, Y. J., Yoo, T., Suh, K., Kang, K. W., Son, M. J., Kim, W. K., & Choi, M. (2025) · Nature Genetics · doi:10.1038/s41588-025-02237-8 · Cited by 45
“One notable example is an ieQTL in HSD17B13 , the inhibitory influence of which exerts a protective effect against MASLD and liver fibrosis 54,55 .”
Outpatient management of alcohol-related liver disease
Simonetto, D. A., Shah, V. H., & Kamath, P. S. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30415-7 · Cited by 32
“Genetic polymorphism of patatin-like phospholipase domain protein 3 (PNPLA3) gene(26), as well as membrane bound O-acyltransferase domain-containing 7 (MBOAT7) and transmembrane 6 superfamily member 2 (TM6SF2) have been shown to confer a higher risk of alcohol-related cirrhosis(32); whereas a variant in HSD17B13, enco…”
BackgroundCharacterization of essential domains in HSD17B13 for cellular localization and enzymatic activity
Ma, Y., Karki, S., Brown, P. M., Lin, D. D., Podszun, M. C., Zhou, W., Belyaeva, O. V., Kedishvili, N. Y., & Rotman, Y. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000907 · Cited by 32
“HSD17B13 is an LD-associated protein (17, 19, 31, 32), and we identified a PAT-like domain at its Nterminus that is essential for its stability, targeting to LD, and enzymatic function (17).”
BackgroundInfluentialZhang, J., Shen, Y., Chen, X.-Y., Jiang, M.-L., Yuan, F.-H., Xie, S.-L., Zhang, J., & Xu, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1115890 · Cited by 39
Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13
(2023) · doi:10.1038/s41467-023-40766-0 · Cited by 29
“This variant was strongly associated with slowed progression of NAFLD toward non-alcoholic steatohepatitis (NASH) and advanced fi brosis 10 .”
InfluentialAssociation of HSD17B13 rs72613567:TA with non‐alcoholic fatty liver disease in Hispanics/Latinos
Kallwitz, E. R., Tayo, B. O., Kuniholm, M. H., Daviglus, M. L., Zeng, D., Isasi, C. R., & Cotler, S. J. (2020) · Liver International · doi:10.1111/liv.14387 · Cited by 30
Benedittis, C. D., Bellan, M., Crevola, M., Boin, E., Barbaglia, M. N., Mallela, V. R., Ravanini, P., Ceriani, E., Fangazio, S., Sainaghi, P. P., et al. (2020) · Gastroenterology Research and Practice · doi:10.1155/2020/4216451 · Cited by 32
Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
Rios, R. S., Zheng, K. I., & Zheng, M.-H. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001888 · Cited by 29
“[65,66]PNPLA3, TM6SF2, andMBOAT7 represent genetic variations related to fat build-up in liver cells while an inhibited HSD17B13 variant was associated with a reduced risk of NAFL to NASH.”
BackgroundSookoian, S. C., & Pirola, C. J. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0318 · Cited by 33
“Likewise, the rs72613567 insertion/deletion variant in HSD17B13 (hydroxysteroid 17-beta-dehydrogenase 13), the functional consequence of which is a splice donor variant of the HSD17B13 (12), presents protective effect against NAFLD and severe histologic outcomes.(12,19,20) The modest effects on NAFLD risk of the rs780…”
BackgroundPrecision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
Valenzuela‐Vallejo, L., Sanoudou, D., & Mantzoros, C. S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050830 · Cited by 33
Genome‐Wide Association Study of Liver Fat: The Multiethnic Cohort Adiposity Phenotype Study
Park, S., Li, Y., Sheng, X., Hom, V., Xia, L. Y., Zhao, K., Pooler, L., Setiawan, V. W., Lim, U., Monroe, K. R., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1533 · Cited by 30
“For rs72613567, the insertion of an A allele in hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) had an inverse relationship with both NAFLD risk and ALT.(48) This inserted allele was found to alter messenger RNA splicing so that the truncated protein reduced enzymatic activity.”
BackgroundSen, P., Govaere, O., Sinioja, T., McGlinchey, A., Geng, D., Ratziu, V., Bugianesi, E., Schattenberg, J. M., Vidal-Puig, A., Allison, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104949 · Cited by 28
Scheiner, B., Stättermayer, A. F., Schwabl, P., Bucsics, T., Paternostro, R., Bauer, D. J. M., Simbrunner, B., Schmidt, R. L. J., Marculescu, R., Ferlitsch, A., et al. (2019) · Liver International · doi:10.1111/liv.14304 · Cited by 30
“well as MELD scores (12 (10-15) vs 11 (9-13) points; P = .”
Metadata
- Authors
- Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., Stepanchick, A. N., Still, M. D., McCarthy, S., O’Dushlaine, C., Packer, J. S., Balasubramanian, S., Gosalia, N., Esopi, D., Kim, S. Y., Mukherjee, S., Lopez, A. E., Fuller, E. D., Penn, J., Chu, X., Luo, J. Z., Mirshahi, U. L., Carey, D. J., Still, C. D., Feldman, M. D., Small, A., Damrauer, S. M., Rader, D. J., Zambrowicz, B., Olson, W., Murphy, A. J., Borecki, I. B., Shuldiner, A. R., Reid, J. G., Overton, J. D., Yancopoulos, G. D., Hobbs, H. H., Cohen, J. C., Gottesman, O., Teslovich, T. M., Baras, A., Mirshahi, T., Gromada, J., & Dewey, F. E.
- Affiliations
- From the Regeneron Genetics Center (N.S.A.-H., A.H.L., C.S., S. McCarthy, C.O., J.S.P., S.B., N.G., S. Mukherjee, A.E.L., E.D.F., J.P., I.B.B., A.R.S., J.G.R., J.D.O., O.G., T.M.T., A.B., F.E.D.) and Regeneron Pharmaceuticals (X. Cheng, Y.X., P.S., Y.L., D.E., S.Y.K., B.Z., W.O., A.J.M., G.D.Y., J.G.), Tarrytown, NY; the University of Texas Southwestern Medical Center at Dallas, Dallas (J.K., S.S., H.H.H., J.C.C.); and Geisinger Health System, Danville (G.C.W., A.N.S., M.D.S., X. Chu, J.Z.L., U.L.M....
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- ORCID
- Cheng, Xiping
- Li, Alexander H.
- Xin, Yurong
- Schurmann, Claudia
- Liu, Yashu
- Kozlitina, Julia
- Stender, Stefan
- Wood, G. Craig
- Still, Matthew D.
- O’Dushlaine, Colm
- Packer, Jonathan S.
- Balasubramanian, Suganthi
- Gosalia, Nehal
- Esopi, David
- Kim, Sun Y.
- Mukherjee, Semanti
- Lopez, Alexander E.
- Chu, Xin
- Luo, Jonathan Z.
- Mirshahi, Uyenlinh L.
- Carey, David J.
- Still, Christopher D.
- Feldman, Michael D.
- Small, Aeron
- Damrauer, Scott M.
- Rader, Daniel J.
- Zambrowicz, Brian
- Olson, William
- Murphy, Andrew J.
- Borecki, Ingrid B.
- Shuldiner, Alan R.
- Reid, Jeffrey G.
- Overton, John D.
- Hobbs, Helen H.
- Cohen, Jonathan C.
- Baras, Aris
- Mirshahi, Tooraj
- Gromada, Jesper
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-22
- Volume
- 378
- Issue
- 12
- Pages
- 1096-1106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6668033
- OpenAlex
- W2793543636
- Cited by
- 827
- References
- 32
- Citations by year
- 2026: 101 · 2025: 104 · 2024: 82 · 2023: 104 · 2022: 100 · 2021: 109 · 2020: 127 · 2019: 67 · 2018: 32
- FWCI
- 48.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Perelman School of Medicine, University of Pennsylvania
- Smilow Foundation
- National Institutes of Health (P30DK072488, UL1TR001105)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- HSD17B13, chronic liver disease, loss-of-function mutations, alcoholic liver disease, non-alcoholic liver disease, alcoholic cirrhosis, non-alcoholic cirrhosis, nonalcoholic steatohepatitis, steatosis, alanine aminotransferase, aspartate aminotransferase, PNPLA3, liver histopathology
- MeSH terms
- Exome Sequencing, Loss of Function Mutation, Alanine Transaminase, Aspartate Aminotransferases, Chronic Disease, Fatty Liver, Female, Genotype, Humans, Liver, Liver Diseases, Male, Genetic Variation, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Linear Models, Sequence Analysis, RNA, Disease Progression, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.